Three female-founded companies pitched to potential investors at The Cannon. Here's why they are ones to watch. Courtesy photos

The Lone Star State has been deemed a great place for female entrepreneurs to get their feet wet, and Houston's ecosystem is full of these leading ladies. At a pitch party at The Cannon, a coworking space in West Houston, over 100 guests, including Cannon Ventures investors and Cannon members, gathered to hear three of these female founders pitch their companies.

From DNA dating and smart pillboxes to an educational franchise company, these three female-led institutions are ones to watch this year. Here's why.

X&Y Technologies

Brittany Barreto wants X&Y Technologies to be known for its science-based dating expertise. Karla Martin/Pheramor

Now is the time to have a DNA-based technology company, says Brittany Barreto, CEO and co-founder of X&Y Technologies. She launched her genetics-based data app over two years ago, and now she's expanding the brand to include a couples compatibility test and B-to-B software-as-a-service feature, so that other dating apps can utilize her technology.

"Our traction with the dating app was a fantastic way to prove that we are the thought leaders, we have the infrastructure, and we have the algorithm and we've proven that the market is ready to buy a DNA kit to find love," she says in her pitch.

With fundraising plans in 2019, Barreto hopes to launch the expanded company, and says she has already seen a lot of interest in both of the new DNA-based products. Read more about Pheramor's national growth, the X&Y expansion, and how Barreto got her start.

IDEA Lab Kids

Ghazal Qureshi pitched her education franchise company, IDEA Lab Kids, and discussed her plans to double its presence in 2019. Natalie Harms/InnovationMap

Six years ago, when Ghazal Qureshi wanted an after school program for her kid and their diverse interests, she created it. Now, the interactive programming that focuses on the science, technology, engineering, arts and math activities for kids is a growing franchise opportunity. After launching the franchise model in February 2017, IDEA Lab Kids already has 10 locations, with seven coming on board within the next few months — including a location in Ecuador.

"In 2019, we're looking to double the number of campuses," Qureshi says in her pitch.

What makes IDEA Lab different from its competitors, she says, is the interactive and diversified curriculum that engages all children.

"We know that kids have limited attention spans theses days," Qureshi says. "New technologies and methods are needed every day in order to grasp that attention span, and that is what we are really good at. At any given day, there are drones flying, augmented reality, cooking classes, and more are happening under the roof of an IDEA Lab campus."

In addition to expanding its presence, Qurshi has worked to roll our new products, such as a coding club, updated website registration tools

EllieGrid

Regina Vatterott is thinking outside the pillbox with her startup, EllieGrid. Courtesy of EllieGrid

When she was in college, Regina Vatterott fainted on her way to lunch. She had lapsed on taking her medicine and vitamins, which caused an imbalance in her health. She was using a traditional pillbox that was tacky and a pain to organize and starting thinking about a product that was more stylish and used smart technology. She and her cofounders created EllieGrid, a sleek pillbox that syncs to your phone to send you messages when its time to take your meds and allows for an easier organization process.

EllieGrid's reception has been great, and the company is expanding to provide users new tools and technology. For instance, EllieGrid is starting to learn more about when its users take its medicine, which can translate to partnerships with insurence companies that currently pay pharmacies to check in with patients who haven't picked up their medicine.

"For us, Ellie is just the start," Vatterott says in an interview with InnovationMap. "We want to develop more health and wellness accessories that are traditionally known to be medical devices."

Large companies are taking interest in the Houston-based startup. Over the past three weeks, Best Buy, Walmart, CVS Health, and Pelion all reached out and expressed interest in the company, some actually placing orders and setting up trials.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

5 Houston scientists named winners of prestigious Hill Prizes 2026

prized research

Five Houston scientists were recognized for their "high-risk, high-reward ideas and innovations" by Lyda Hill Philanthropies and the Texas Academy of Medicine, Engineering, Science and Technology (TAMEST).

The 2026 Hill Prizes provide seed funding to top Texas researchers. This year's prizes were given out in seven categories, including biological sciences, engineering, medicine, physical sciences, public health and technology, and the new artificial intelligence award.

Each recipient’s institution or organization will receive $500,000 in direct funding from Dallas-based Lyda Hill Philanthropies. The organization has also committed to giving at least $1 million in discretionary research funding on an ad hoc basis for highly-ranked applicants who were not selected as recipients.

“It is with great pride that I congratulate this year’s Hill Prizes recipients. Their pioneering spirit and unwavering dedication to innovation are addressing some of the most pressing challenges of our time – from climate resilience and energy sustainability to medical breakthroughs and the future of artificial intelligence,” Lyda Hill, founder of Lyda Hill Philanthropies, said in a news release.

The 2026 Houston-area recipients include:

Biological Sciences: Susan M. Rosenberg, Baylor College of Medicine

Rosenberg and her team are developing ways to fight antibiotic resistance. The team will use the funding to screen a 14,000-compound drug library to identify additional candidates, study their mechanisms and test their ability to boost antibiotic effectiveness in animal models. The goal is to move toward clinical trials, beginning with veterans suffering from recurrent infections.

Medicine: Dr. Raghu Kalluri, The University of Texas MD Anderson Cancer Center

Kalluri is developing eye drops to treat age-related macular degeneration (AMD), the leading cause of vision loss globally. Kalluri will use the funding to accelerate studies and support testing for additional ocular conditions. He was also named to the National Academy of Inventors’ newest class of fellows last month.

Engineering: Naomi J. Halas, Rice University

Co-recipeints: Peter J. A. Nordlander and Hossein Robatjazi, Rice University

Halas and her team are working to advance light-driven technologies for sustainable ammonia synthesis. The team says it will use the funding to improve light-driven catalysts for converting nitrogen into ammonia, refine prototype reactors for practical deployment and partner with industry collaborators to advance larger-scale applications. Halas and Nordlander are co-founders of Syzygy Plasmonics, and Robatjazi serves as vice president of research for the company.

The other Texas-based recipients include:

  • Artificial Intelligence: Kristen Grauman, The University of Texas at Austin
  • Physical Sciences: Karen L. Wooley, Texas A&M University; Co-Recipient: Matthew Stone, Teysha Technologies
  • Public Health: Dr. Elizabeth C. Matsui, The University of Texas at Austin and Baylor College of Medicine
  • Technology: Kurt W. Swogger, Molecular Rebar Design LLC; Co-recipients: Clive Bosnyak, Molecular Rebar Design, and August Krupp, MR Rubber Business and Molecular Rebar Design LLC

Recipients will be recognized Feb. 2 during the TAMEST 2026 Annual Conference in San Antonio. They were determined by a committee of TAMEST members and endorsed by a committee of Texas Nobel and Breakthrough Prize Laureates and approved by the TAMEST Board of Directors.

“On behalf of TAMEST, we are honored to celebrate the 2026 Hill Prizes recipients. These outstanding innovators exemplify the excellence and ambition of Texas science and research,” Ganesh Thakur, TAMEST president and a distinguished professor at the University of Houston, added in the release. “Thanks to the visionary support of Lyda Hill Philanthropies, the Hill Prizes not only recognize transformative work but provide the resources to move bold ideas from the lab to life-changing solutions. We are proud to support their journeys and spotlight Texas as a global hub for scientific leadership.”

Investment bank opens new Houston office focused on energy sector

Investment bank Cohen & Co. Capital Markets has opened a Houston office to serve as the hub of its energy advisory business and has tapped investment banking veteran Rahul Jasuja as the office’s leader.

Jasuja joined Cohen & Co. Capital Markets, a subsidiary of financial services company Cohen & Co., as managing director, and head of energy and energy transition investment banking. Cohen’s capital markets arm closed $44 billion worth of deals last year.

Jasuja previously worked at energy-focused Houston investment bank Mast Capital Advisors, where he was managing director of investment banking. Before Mast Capital, Jasuja was director of energy investment banking in the Houston office of Wells Fargo Securities.

“Meeting rising [energy] demand will require disciplined capital allocation across traditional energy, sustainable fuels, and firm, dispatchable solutions such as nuclear and geothermal,” Jasuja said in a news release. “Houston remains the center of gravity where capital, operating expertise, and execution come together to make that transition investable.”

The Houston office will focus on four energy verticals:

  • Energy systems such as nuclear and geothermal
  • Energy supply chains
  • Energy-transition fuel and technology
  • Traditional energy
“We are making a committed investment in Houston because we believe the infrastructure powering AI, defense, and energy transition — from nuclear to rare-earth technology — represents the next secular cycle of value creation,” Jerry Serowik, head of Cohen & Co. Capital Markets, added in the release.

---

This article originally appeared on EnergyCaptialHTX.com.

MD Anderson makes AI partnership to advance precision oncology

AI Oncology

Few experts will disagree that data-driven medicine is one of the most certain ways forward for our health. However, actually adopting it comes at a steep curve. But what if using the technology were democratized?

This is the question that SOPHiA GENETICS has been seeking to answer since 2011 with its universal AI platform, SOPHiA DDM. The cloud-native system analyzes and interprets complex health care data across technologies and institutions, allowing hospitals and clinicians to gain clinically actionable insights faster and at scale.

The University of Texas MD Anderson Cancer Center has just announced its official collaboration with SOPHiA GENETICS to accelerate breakthroughs in precision oncology. Together, they are developing a novel sequencing oncology test, as well as creating several programs targeted at the research and development of additional technology.

That technology will allow the hospital to develop new ways to chart the growth and changes of tumors in real time, pick the best clinical trials and medications for patients and make genomic testing more reliable. Shashikant Kulkarni, deputy division head for Molecular Pathology, and Dr. J. Bryan, assistant professor, will lead the collaboration on MD Anderson’s end.

“Cancer research has evolved rapidly, and we have more health data available than ever before. Our collaboration with SOPHiA GENETICS reflects how our lab is evolving and integrating advanced analytics and AI to better interpret complex molecular information,” Dr. Donna Hansel, division head of Pathology and Laboratory Medicine at MD Anderson, said in a press release. “This collaboration will expand our ability to translate high-dimensional data into insights that can meaningfully advance research and precision oncology.”

SOPHiA GENETICS is based in Switzerland and France, and has its U.S. offices in Boston.

“This collaboration with MD Anderson amplifies our shared ambition to push the boundaries of what is possible in cancer research,” Dr. Philippe Menu, chief product officer and chief medical officer at SOPHiA GENETICS, added in the release. “With SOPHiA DDM as a unifying analytical layer, we are enabling new discoveries, accelerating breakthroughs in precision oncology and, most importantly, enabling patients around the globe to benefit from these innovations by bringing leading technologies to all geographies quickly and at scale.”